share_log

Alliance Global Partners Initiates Coverage On NeuroSense Therapeutics With Buy Rating, Announces Price Target of $7.5

Alliance Global Partners Initiates Coverage On NeuroSense Therapeutics With Buy Rating, Announces Price Target of $7.5

Alliance Global Partners以買入評級開始對NeuroSense Therapeutics進行報道,宣佈目標
Benzinga ·  2023/07/17 10:25

Alliance Global Partners analyst James Molloy initiates coverage on NeuroSense Therapeutics (NASDAQ:NRSN) with a Buy rating and announces Price Target of $7.5.

Alliance Global Partners分析師詹姆斯·莫洛伊開始報道NeuroSense Therapeutics(納斯達克股票代碼:NRSN),評級爲買入,並宣佈目標股價爲7.5美元

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論